Special Issue "Marine Chitin and Chitosan"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (28 February 2010)

Special Issue Editor

Guest Editor
Prof. Dr. Riccardo A. A. Muzzarelli
Via Volterra, 7, 60123 Ancona, Italy
Website: http://www.chitin.it/
E-Mail: muzzarelli.raa@gmail.com
Phone: +39-071-36206
Fax: +39-071-36206

Special Issue Information

Dear Colleagues,

Chitin can be interpreted as the most abundant organic compound of nitrogen. Current sources are the crustacean shells isolated as by-products of canning / freezing operations in marine food factories. Mechanical peeling and enzyme inactivation are pre-requisites for treating the chitin-bearing biomass. Immediately after isolation, chitin is transformed into chitosans of various grades. Chemical, physical and enzymatic deacetylation methods are available for the production of chitosan, the sole abundantly accessible cationic polysaccharide. Manipulation of the molecular weight leads to water-soluble chitosans: the randomly 50 % deacetylated, and the partially depolymerized chitosans are water-soluble. Advanced water-soluble modified chitosans are also available, as well as new solvent systems. Purification methods from proteins, carotenoids and inorganics enable to produce chitosans of technical, food, pharmaceutical and medical grades, that are officially recognized as safe in a large number of countries. The industrial production of N-acetylglucosamine and glucosamine is based on the depolymerization of chitosan from marine crustaceans. Due to different crystallinity, chitosan obtained from squid chitin is more prone to chemical modification because the nanofibrillar structure of chitin and chitosan has a certain technical significance. Chitosans in novel physico-chemical forms include composites, electrospun nanofibers, polyelectrolyte complexes, blends with neutral polysaccharides (cellulose, starch...), silylated and otherwise cross-linked chitosans, metal ion chelates, and films for marine food protection. Chitin and chitosan are not drugs sensu stricto, but exhibit peculiar characteristics that recently qualified them in the biomedical field, for example as carriers for drug delivery, chitosan being the best DNA vector for gene therapy. Chitosan exerts immuno-stimulating effects, and it is not seen as a foreign body by human cells. The antimicrobial activity of chitosans has been elucidated for numerous bacteria and some fungi. This special issue is expected to encourage a wider exploitation of the marine chitin resources, and the scaling-up of certain applications, particularly in the pharmaceutical area.

Prof. Dr. Riccardo A.A. Muzzarelli
Guest Editor

Related Special Issues

Keywords

  • chitin
  • chitosan
  • crustaceans
  • squid
  • quality assessment
  • N-acetylglucosamine
  • glucosamine
  • pharmaceuticals
  • antimicrobials
  • drug carriers

Published Papers (14 papers)

Mar. Drugs 2010, 8(9), 2493-2516; doi:10.3390/md8092493
Received: 22 March 2010; in revised form: 19 April 2010 / Accepted: 23 April 2010 / Published: 15 September 2010
Show/Hide Abstract | Download PDF Full-text (427 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(7), 2212-2222; doi:10.3390/md8072212
Received: 16 June 2010; in revised form: 3 July 2010 / Accepted: 7 July 2010 / Published: 23 July 2010
Show/Hide Abstract | Download PDF Full-text (340 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(7), 1988-2012; doi:10.3390/md8071988
Received: 2 May 2010; in revised form: 24 May 2010 / Accepted: 8 June 2010 / Published: 28 June 2010
Show/Hide Abstract | Download PDF Full-text (268 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(7), 1962-1987; doi:10.3390/md8071962
Received: 20 April 2010; in revised form: 29 May 2010 / Accepted: 9 June 2010 / Published: 25 June 2010
Show/Hide Abstract | Download PDF Full-text (310 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(6), 1750-1762; doi:10.3390/md8061750
Received: 10 March 2010; in revised form: 23 April 2010 / Accepted: 17 May 2010 / Published: 26 May 2010
Show/Hide Abstract | Download PDF Full-text (378 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(5), 1716-1730; doi:10.3390/md8051716
Received: 9 March 2010; in revised form: 23 March 2010 / Accepted: 6 April 2010 / Published: 25 May 2010
Show/Hide Abstract | Download PDF Full-text (205 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(5), 1699-1715; doi:10.3390/md8051699
Received: 9 March 2010; in revised form: 15 April 2010 / Accepted: 26 April 2010 / Published: 25 May 2010
Show/Hide Abstract | Download PDF Full-text (168 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(5), 1567-1636; doi:10.3390/md8051567
Received: 8 March 2010; in revised form: 30 March 2010 / Accepted: 27 April 2010 / Published: 29 April 2010
Show/Hide Abstract | Download PDF Full-text (1140 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2010, 8(5), 1518-1525; doi:10.3390/md8051518
Received: 27 March 2010; in revised form: 23 April 2010 / Accepted: 26 April 2010 / Published: 28 April 2010
Show/Hide Abstract | Download PDF Full-text (137 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Mar. Drugs 2010, 8(5), 1482-1517; doi:10.3390/md8051482
Received: 5 March 2010; in revised form: 14 April 2010 / Accepted: 23 April 2010 / Published: 27 April 2010
Show/Hide Abstract | Download PDF Full-text (1047 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(4), 1305-1322; doi:10.3390/md8041305
Received: 9 February 2010; in revised form: 17 March 2010 / Accepted: 22 March 2010 / Published: 19 April 2010
Show/Hide Abstract | Download PDF Full-text (385 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(4), 968-987; doi:10.3390/md8040968
Received: 12 March 2010; in revised form: 24 March 2010 / Accepted: 29 March 2010 / Published: 30 March 2010
Show/Hide Abstract | Download PDF Full-text (134 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(2), 292-312; doi:10.3390/md8020292
Received: 27 January 2010; Accepted: 20 February 2010 / Published: 21 February 2010
Show/Hide Abstract | Download PDF Full-text (161 KB) | View HTML Full-text | Download XML Full-text

Mar. Drugs 2010, 8(1), 24-46; doi:10.3390/md8010024
Received: 24 December 2009; in revised form: 8 January 2010 / Accepted: 11 January 2010 / Published: 14 January 2010
Show/Hide Abstract | Download PDF Full-text (271 KB) | View HTML Full-text | Download XML Full-text
abstract graphic

Last update: 27 February 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert